VESICARE 10mg price in UAE

Overview

Welcome to Dwaey, specifically on VESICARE 10mg Tablets/Film-coated page.
This medicine contains an important and useful components, as it consists of Solifenacin succinate.
VESICARE 10mg is available in the market in concentration 10mg/Tablet and in the form of Tablets/Film-coated.

SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO. LTD (SAJA) is the producer of VESICARE 10mg and it is imported from SAUDI ARABIA, The most popular alternatives of VESICARE 10mg are listed downward .

Mode Of Action

Solifenacin is a selective M3 antimuscarinic that inhibits muscarinic receptors resulting in decreased urinary bladder contraction, increased residual urine volume and decreased detrusor muscle pressure.

Indication

Overactive bladder

Precaution

Increased risk of urinary retention in patients with bladder outflow obstruction. Caution in patients with decreased GI motility, GI obstructive diseases, controlled narrow-angle glaucoma, liver or kidney impairment, patients with known history of QT prolongation or other risk factors for QT prolongation. May cause drowsiness and/or blurred vision. Monitor serum creatinine clearance and liver function. Maintain adequate hydration. Increased susceptibility to heat prostration due to reduced ability to sweat. Pregnancy, lactation.

Side Effects

Constipation
dyspepsia
nausea
upper abdominal pain
xerostomia
hypertension
oedema
headache
depression
fatigue
urinary tract infection
blurred vision
cough
influenza.

Contra indication

Uncontrolled narrow-angle glaucoma, urinary retention, gastric retention.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

May interfere with the prokinetic effects of cisapride and metoclopramide. Potentially Fatal: May reduce the stimulatory effect of secretin. Concurrent use with biperiden, orphenadrine, procyclidine or trihexyphenidyl may cause anticholinergic effects such as confusion and loss of bladder control; a washout period of 1 wk between using these drugs is recommended. May increase the ulcerogenic effect of potassium chloride. Strong CYP3A4 inhibitors (e.g. ketoconazole, fluconazole, itraconazole, erythromycin, telithromycin, clarithromycin, ritonavir, indinavir, nelfinavir, nefazodone, aprepitant, verapamil) may reduce the metabolism of solifenacin, thus increasing its plasma levels.